Overview

The Genetic Technology (Gene Technology Regulatory Scheme) Act 2000, enacted in 2000, aims to regulate the use of gene technology to ensure the protection of human health and safety and the environment. This Act establishes the legislative framework for the regulation of genetically modified organisms (GMOs) in Australia, addressing the need for a structured approach to managing the potential risks associated with gene technology. The Act was enacted by the Australian Parliament with the policy objective of providing a balanced approach to the regulation of GMOs, facilitating innovation while ensuring public safety and environmental protection. In 2013, the Gene Technology Regulator issued an invitation for public comment on Licence Application DIR 119, proposing a field trial for genetically modified narrow-leafed lupins at the New Genes for New Environments facility in Merredin, Western Australia. The trial, conducted by the University of Western Australia, aims to assess the plants' tolerance to glyphosate under field conditions. The Regulator is inviting submissions to finalize the Risk Assessment and Risk Management Plan (RARMP) before making a decision on whether to issue the licence. The RARMP and related documents are available for review on the Office of the Gene Technology Regulator's website, with submissions due by 28 March 2013.

Scope and Application

The Gene Technology Act 2000, which governs the regulation of genetically modified organisms in Australia, applies to the proposed field trial of genetically modified narrow-leafed lupin plants at the New Genes for New Environments facility in Merredin, Western Australia. This Act establishes the framework under which the Gene Technology Regulator assesses and regulates activities involving genetically modified organisms to safeguard public health and the environment. The proposed trial, submitted by the University of Western Australia, is subject to the provisions of this Act, which includes the preparation of a Risk Assessment and Risk Management Plan (RARMP) to evaluate potential risks and establish conditions for the trial. This Act applies to the entities and individuals involved in the proposed trial, including the University of Western Australia, and extends to the specified geographic location and timeframe of the trial, from May 2013 to April 2015. The Act also mandates public consultation, as evidenced by the current invitation for submissions regarding the RARMP. The application process and subsequent licencing decisions are made in accordance with the Act, which allows for the imposition of specific licence conditions to mitigate identified risks. The Act applies nationally across Australia, with the Office of the Gene Technology Regulator in Canberra overseeing its implementation. There are no explicit exclusions or exemptions detailed for this specific trial, although the Act provides for exclusions under certain circumstances, such as for research and development purposes. The Act may also be supplemented by subordinate legislation, which can further define the scope and application of the regulatory framework.

Key Provisions

The main operative sections of the legislation detail the conditions under which the genetically modified (GM) narrow-leafed lupin can be released, specifically under Licence Application DIR 119 (section 1). The field trial is to be conducted under strict guidelines, ensuring that the GM lupin does not enter human food or animal feed supply chains (section 2). The application process involves a comprehensive Risk Assessment and Risk Management Plan (RARMP) that evaluates potential risks to human health and the environment (section 3). Draft licence conditions are proposed to manage the size, location, duration, and genetic material spread of the trial (section 4). The Act imposes several obligations on the parties involved. The University of Western Australia must adhere to the conditions set forth in the RARMP and the draft licence conditions (section 5). These conditions include restricting the trial to a maximum area of 0.5 hectares per growing season, limiting the duration of the trial from May 2013 to April 2015, and ensuring that the GM lupin remains within the confines of the New Genes for New Environments facility in Merredin, Western Australia (section 6). The trial must also incorporate measures to prevent the GM lupin from spreading beyond the designated area and to manage the persistence of the introduced genetic material (section 7). Breaches of the conditions set out in the legislation could lead to various civil and criminal consequences. The Gene Technology Act 2000 provides for both civil and criminal penalties for non-compliance with licence conditions (section 8). Civil penalties include fines up to a specified maximum amount, as determined by the relevant authorities (section 9). Criminal penalties can include fines and imprisonment, with the exact penalties varying based on the severity and frequency of the breach (section 10). The Gene Technology Regulator has the authority to enforce these penalties to ensure compliance and to protect public health and the environment (section 11).